Document ID: chunk:federal_register_of_legislation:F2016L00560:reg:9:p5
Version: federal_register_of_legislation:F2016L00560
Segment Type: reg
Provision Reference: reg 9 (pt 5/6)
Character Range: 16809–19880

months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(21)      being exposed to manganese as specified for a cumulative period of at least 250 hours, within the ten years before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: being exposed to manganese as specified is defined in the Schedule 1 - Dictionary.
(22)      having clinical or biochemical evidence of manganese intoxication while receiving total parenteral nutrition or maintenance haemodialysis, at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: total parenteral nutrition is defined in the Schedule 1 - Dictionary.
(23)      inhaling, ingesting or having cutaneous contact with cyanide, and having clinical, haematological or biochemical evidence of cyanide intoxication, within the three months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(24)      having an injection containing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) within the three months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(25)      using khat (Catha edulis), Ecstasy (3,4-methylenedioxymethamphetamine) or the drug methcathinone (ephedrone) within the three months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(26)      taking a drug or a drug from a class of drugs from the specified list of drugs, for a continuous period of at least seven days within the three months before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(27)      having a disorder of calcium metabolism from the specified list of disorders of calcium metabolism at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: specified list of disorders of calcium metabolism is defined in the Schedule 1 - Dictionary.
(28)      having cirrhosis of the liver at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
(29)      having chronic renal failure at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
(30)      an inability to undertake any physical activity greater than three METs for at least the five years before the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: MET is defined in the Schedule 1 - Dictionary.
(31)      having a disease from the specified list of autoimmune diseases at the time of the clinical worsening of Parkinson's disease or secondary parkinsonism;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(32)      consuming an average of at least one litre of milk per day for at least the five years before the clinical worsening of Parkinson's disease or secondary parkinsonism;
(33)      consuming an average of at least 150 grams of cheese per day for at least the five years